Cohance Lifesciences Ltd Q1 FY27 Earnings Analysis

- FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable. - Recovery order: API segment first, followed by CDMO and Specialty Chemicals. - Growth driven by execution on existing programs, customer conversions, reloads, and improved asset utilization. - Pipeline strengthened with 10 Phase 3 programs; 2 programs recently commercialized and others progressing well. - New molecule launches ongoing, with 4 commercial launches planned across FY26 and FY27. - Increase in customer base and diversification efforts underway to reduce dependency on a few molecules. - Expansion in ADC, oligonucleotide, and small molecule capabilities expected to drive future growth. - Business moving towards a bottoming-out phase, signaling potential stabilization and growth going forward. - Capex of INR 3 billion planned in FY27 to support manufacturing infrastructure and quality systems.

- Growth is expected to return from the second half of FY27, with Q1 FY27 being weak in both revenue and EBITDA due to revenue schedules skewed towards H2 and cost pressures (Page 4). - Recovery order: API segment is expected to recover first, followed by CDMO and then Specialty Chemicals (Page 10). - Expansion of customer base and acceleration of later phase projects in CDMO to drive growth, with small molecule segment funnel having doubled in six months (Page 11). - Addition of new molecules: Two molecules have already launched commercially; two more expected within the next 12-18 months, depending on clinical performance, potentially contributing to revenue growth in H2 FY27 (Page 11). - Pipeline strength: Total of 10 Phase 3 programs with some moving to commercialization, supporting medium-term growth (Page 3). - Operational improvements and cost actions, alongside brand-building and SG&A investments, expected to enhance margins over time (Page 11). - Full year FY27 guidance not yet provided; management to share once clarity improves (Page 8).

- Capex during FY26 was INR 2.15 billion, focused on ADC, oligonucleotides, manufacturing infrastructure, and quality systems. - Capex spend expected to be nearly INR 3 billion in FY27. - Investment ongoing in NJ Bio to support bioconjugation programs for Phase 1 and Phase 2; implementation expected to take about one year plus validation time, with recovery in over two years. - Strategic focus on strengthening operational rigor, quality systems, and science capabilities including ADCs and oligonucleotide chemistries. - Evaluation and exploration of AI tools for improving operational efficiencies, regulatory filings, and decision-making through data lakes/databases.

- There is no explicit mention of any ongoing or planned fundraising through debt or equity in the provided transcript. - The company reported free cash flow generation of INR1.73 billion in FY26 and outlined capex plans of around INR3 billion for FY27, indicating internal funding for growth and expansion. - Management discussed focusing on operational efficiencies, product pipeline development, and business recovery rather than raising external capital at this stage. - No specific guidance or commentary was provided regarding new debt or equity issuance during the call.

- The company reported an active and growing order book, especially in the Phase 1 and Phase 2 programs with strong quality customers. - The Phase 3 pipeline increased to 10 programs, with two programs progressing toward commercialization. - They experienced healthy reload conversion above 90% and good new business conversions with innovator pharma and biotech customers. - The CDMO business is focusing on expanding the customer base and onboarding later-phase projects to accelerate revenue recovery. - FY27 is seen as a qualification and readiness year for parts of the portfolio, with supplies expected to build as customer programs progress. - Growth is expected to return in FY28 as customer programs convert into revenue. - Discussions and negotiations with customers about the return of business from molecules with a prior drawdown are ongoing, but no exact orderbook figures disclosed.